Heat-shock protein 90 (Hsp90) promotes opioid-induced anti-nociception by an ERK mitogen-activated protein kinase (MAPK) mechanism in mouse brain
Name:
J.Biol.Chem.-2017-Lei-10414-28.pdf
Size:
2.871Mb
Format:
PDF
Description:
Final Accepted Manuscript
Author
Lei, WeiMullen, Nathan
McCarthy, Sarah
Brann, Courtney
Richard, Philomena
Cormier, James
Edwards, Katie
Bilsky, Edward J.
Streicher, John M.
Affiliation
Univ Arizona, Coll Med, Dept PharmacolIssue Date
2017-06-23
Metadata
Show full item recordCitation
Lei W, Mullen N, McCarthy S, Brann C, Richard P, Cormier J, Edwards K, Bilsky EJ, and Streicher JM. 2017. Heat Shock Protein 90 (Hsp90) Promotes Opioid-Induced Anti-Nociception by an ERK Mitogen Activated Protein Kinase (MAPK) Mechanism in Mouse Brain. Journal of Biological Chemistry. 292(25):10414-10428. doi:10.1074/jbc.M116.769489Journal
Journal of Biological ChemistryRights
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Recent advances in developing opioid treatments for pain with reduced side effects have focused on the signaling cascades of the μ-opioid receptor (MOR). However, few such signaling targets have been identified for exploitation. To address this need, we explored the role of heat-shock protein 90 (Hsp90) in opioid-induced MOR signaling and pain, which has only been studied in four previous articles. First, in four cell models of MOR signaling, we found that Hsp90 inhibition for 24 h with the inhibitor 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) had different effects on protein expression and opioid signaling in each line, suggesting that cell models may not be reliable for predicting pharmacology with this protein. We thus developed an in vivo model using CD-1 mice with an intracerebroventricular injection of 17-AAG for 24 h. We found that Hsp90 inhibition strongly blocked morphine-induced anti-nociception in models of post-surgical and HIV neuropathic pain but only slightly blocked anti-nociception in a naive tail-flick model, while enhancing morphine-induced precipitated withdrawal. Seeking a mechanism for these changes, we found that Hsp90 inhibition blocks ERK MAPK activation in the periaqueductal gray and caudal brain stem. We tested these signaling changes by inhibiting ERK in the above-mentioned pain models and found that ERK inhibition could account for all of the changes in anti-nociception induced by Hsp90 inhibition. Taken together, these findings suggest that Hsp90 promotes opioid-induced anti-nociception by an ERK mechanism in mouse brain and that Hsp90 could be a future target for improving the therapeutic index of opioid drugs.Note
12 month embargo; published online: 27 April 2017ISSN
0021-92581083-351X
Version
Final accepted manuscriptAdditional Links
http://www.jbc.org/lookup/doi/10.1074/jbc.M116.769489ae974a485f413a2113503eed53cd6c53
10.1074/jbc.M116.769489